AMN Healthcare Services
AMN
36.53
-0.20
-0.54%
AMN Healthcare Services
US · AMN
#3031 by market cap
Listed 1970
36.53
-0.20
-0.54%
Live - 5344 symbols - heartbeat 240s ago
· 2026-10-08 07:21
Pre-market
36.63
+0.27%
After-hours
36.53
0.00%
- Market cap
- 1.41B
- P/E (TTM)i
- 13.58
- P/Bi
- 1.91
- EPSi
- -2.48
- Div yieldi
- 0.00%
- 52W posi
- 92%
Reader sentiment
Are you bullish or bearish on AMN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.73, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -8.49% YoY
Margins
- Gross margin
- 28.35%
- Operating margin
- 1.21%
- Net margin
- -3.51%
Key ratios & quality
- Enterprise valuei
- 2.15B
- Altman Z-Scorei
- 2.73
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.14B | 2.22B | 2.39B | 3.98B | 5.24B | 3.79B | 2.98B | 2.73B |
| Gross profit | 696.38M | 743.47M | 791.78M | 1.31B | 1.72B | 1.25B | 919.38M | 774.06M |
| Selling & admin expenses | 452.32M | 508.03M | 549.75M | 730.45M | 936.58M | 748.44M | 632.49M | 593.02M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 202.83M | 176.92M | 149.27M | 478.00M | 647.10M | 346.23M | 119.78M | 33.17M |
| Pretax profit | 186.69M | 148.49M | 91.52M | 443.92M | 606.70M | 284.29M | -172.57M | -101.06M |
| Tax | 44.94M | 34.50M | 20.86M | 116.53M | 162.65M | 73.61M | -25.60M | -5.36M |
| Net profit | 141.74M | 113.99M | 70.67M | 327.39M | 444.05M | 210.68M | -146.98M | -95.70M |
| Basic EPS | 3 | 2 | 1 | 7 | 10 | 5 | -4 | -2 |
| Diluted EPS | 2.91 | 2.40 | 1.48 | 6.81 | 9.90 | 5.36 | -3.85 | -2.48 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 689.53M | 658.18M | 634.50M | 748.23M | 1.38B | 673.24M |
| Gross profit | 198.12M | 196.40M | 184.41M | 195.13M | 368.84M | 205.88M |
| Selling & admin expenses | 147.73M | 154.58M | 138.59M | 152.11M | 218.43M | 147.39M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 12.51M | 4.06M | 8.44M | 8.16M | 117.17M | 26.91M |
| Pretax profit | 183.00K | -135.08M | 37.99M | -4.16M | 110.46M | 19.90M |
| Tax | 1.28M | -18.87M | 8.70M | 3.53M | 48.29M | -1.26M |
| Net profit | -1.09M | -116.20M | 29.29M | -7.70M | 62.17M | 21.16M |
| Basic EPS | 0 | -3 | 1 | 0 | 2 | 1 |
| Diluted EPS | -0.03 | -3.02 | 0.76 | -0.20 | 1.59 | 0.53 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 482.17M | 560.50M | 533.74M | 1.35B | 1.09B | 841.69M | 594.92M | 545.38M |
| Cash & ST investments | 13.86M | 82.99M | 29.21M | 180.93M | 64.52M | 32.94M | 10.65M | 33.97M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.49B | 1.93B | 2.35B | 3.13B | 2.89B | 2.92B | 2.42B | 2.09B |
| Total current liabilities | 307.27M | 378.11M | 422.96M | 969.39M | 857.93M | 656.12M | 545.79M | 577.61M |
| Short-term debt | -- | 13.94M | 19.72M | 11.38M | 8.09M | 7.99M | 6.20M | 6.01M |
| Long-term debt | 440.61M | 617.16M | 857.96M | 842.32M | 843.51M | 1.30B | 1.06B | 767.05M |
| Total liabilities | 853,731,000.00 | 1,194,904,000.00 | 1,533,830,000.00 | 1,969,879,000.00 | 1,844,717,000.00 | 2,093,138,000.00 | 1,709,107,000.00 | 1,452,001,000.00 |
| Total equity | 638.99M | 736.74M | 819.68M | 1.16B | 1.04B | 831.26M | 706.62M | 642.11M |
| Retained earnings | 286.06M | 400.05M | 469.56M | 796.95M | 1.24B | 1.45B | 1.30B | 1.21B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 627.36M | 571.35M | 570.32M | 545.38M | 1.14B | 869.26M |
| Cash & ST investments | 55.78M | 41.50M | 52.64M | 33.97M | 560.74M | 361.84M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 2.40B | 2.21B | 2.14B | 2.09B | 2.60B | 2.36B |
| Total current liabilities | 582.25M | 573.64M | 542.16M | 577.61M | 1.04B | 770.49M |
| Short-term debt | 6.57M | 6.28M | 6.14M | 6.01M | 5.80M | 5.79M |
| Long-term debt | 996.17M | 916.46M | 846.76M | 767.05M | 742.49M | 742.94M |
| Total liabilities | 1,680,072,000.00 | 1,604,625,000.00 | 1,494,542,000.00 | 1,452,001,000.00 | 1,891,567,000.00 | 1,622,699,000.00 |
| Total equity | 715.05M | 607.60M | 644.41M | 642.11M | 712.81M | 741.28M |
| Retained earnings | 1.30B | 1.19B | 1.22B | 1.21B | 1.27B | 1.29B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 226.99M | 224.86M | 256.83M | 305.36M | 653.73M | 372.17M | 320.42M | 269.46M |
| Depreciation & amortization | 41.24M | 58.52M | 94.19M | 103.70M | 137.11M | 160.93M | 173.78M | 156.60M |
| Free cash flow | 190.61M | 188.40M | 217.72M | 251.69M | 572.81M | 266.78M | 239.53M | 233.83M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -67.01M | -18.71M | 0 | -2.69M | -576.77M | -424.74M | 0 | 0 |
| Ending cash balance | 84.32M | 153.96M | 83.99M | 246.71M | 137.87M | 108.27M | 89.31M | 67.17M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 92.67M | 78.55M | 22.67M | 75.57M | 562.45M | -189.93M |
| Depreciation & amortization | 39.86M | 39.89M | 39.63M | 37.23M | 35.66M | 34.10M |
| Free cash flow | 82.70M | 68.75M | 14.76M | 67.63M | 555.21M | -198.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 94.72M | 72.45M | 82.89M | 67.17M | 594.98M | 390.48M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 23.59 | 16.57 | 9.08 | 33.04 | 40.26 | 22.47 | -19.11 | -14.19 |
| ROA %i | 10.32 | 6.66 | 3.30 | 11.94 | 14.75 | 7.25 | -5.50 | -4.24 |
| ROIC %i | 15.70 | 10.64 | 7.13 | 18.53 | 24.08 | 12.27 | -4.39 | -3.23 |
| 5-year avg ROE %i | 23.49 | 24.00 | 20.40 | 21.70 | 24.51 | 24.29 | 17.15 | 12.49 |
| EBIT margin %i | 9.50 | 7.96 | 6.24 | 12.00 | 12.34 | 8.93 | -3.44 | -2.03 |
| FCF / sales %i | 8.92 | 8.48 | 9.10 | 6.32 | 10.92 | 7.04 | 8.03 | 8.56 |
| Current ratioi | 1.57 | 1.48 | 1.26 | 1.39 | 1.27 | 1.28 | 1.09 | 0.94 |
| Quick ratioi | 1.40 | 1.36 | 1.13 | 1.25 | 1.19 | 1.19 | 0.97 | 0.82 |
| Debt / assetsi | 29.52 | 37.39 | 40.60 | 27.69 | 29.81 | 46.17 | 45.44 | 38.36 |
| LT debt / equityi | 68.95 | 96.15 | 114.16 | 73.64 | 81.72 | 161.48 | 154.48 | 124.15 |
| Interest coveragei | 12.56 | 6.22 | 2.59 | 14.03 | 16.02 | 6.25 | -1.47 | -1.22 |
| Revenue CAGR (3Y) %i | 13.44 | 5.32 | 6.38 | 23.10 | 33.13 | 16.55 | -9.19 | -19.55 |
| Net income CAGR (3Y) %i | 20.07 | 2.50 | -18.92 | 32.19 | 57.35 | 43.93 | -- | -- |
| FCF CAGR (3Y) %i | 86.67 | 18.95 | 17.57 | 9.71 | 44.87 | 7.01 | -1.64 | -25.82 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -21.08 | -40.13 | -35.90 | -14.19 | -4.54 | 15.56 |
| ROA %i | -6.28 | -11.95 | -11.46 | -4.24 | -1.30 | 4.59 |
| ROIC %i | -5.61 | -13.39 | -12.65 | -3.23 | -0.52 | 8.29 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.56 | -10.52 | -9.80 | -2.03 | 1.44 | 5.82 |
| FCF / sales %i | 9.08 | 9.22 | 8.20 | 8.56 | 20.66 | 12.77 |
| Current ratioi | 1.08 | 1.00 | 1.05 | 0.94 | 1.09 | 1.13 |
| Quick ratioi | 0.94 | 0.87 | 0.94 | 0.82 | 0.96 | 1.03 |
| Debt / assetsi | 43.30 | 43.20 | 41.37 | 38.36 | 29.83 | 32.82 |
| LT debt / equityi | 144.11 | 156.27 | 136.37 | 124.15 | 108.18 | 103.88 |
| Interest coveragei | -1.98 | -4.76 | -4.72 | -1.22 | 1.23 | 5.61 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Nurse and allied solutions is the largest reported line at 62.68% of revenue, across 3 reported segments.
- Physician and leadership solutions follows at 24.45%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Nurse and allied solutions62.68%
Physician and leadership solutions24.45%
Technology and workforce solutions12.88%
Quote time 2026-10-08 07:21:14 · For reference only, not investment advice and not tailored to your situation.